BGB-11417-201 (ClinicalTrials.gov identifier: NCT05471843) is an ongoing global, open-label, phase I/II trial. Sonrotoclax was orally administered once daily with gradual, 4-week ramp-up to 160 mg or ...
Abstract: The utilization of poly-Si/SiO x structures for passivating contacts, commonly referred to as TOPCon (Tunnel Oxide Passivated Contacts), presents a significant opportunity to enhance the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results